Laboratory of Immunogenomics, Zhoushan Hospital-BIG/CAS, Zhoushan 316004, China.
Anat Rec (Hoboken). 2012 Feb;295(2):208-14. doi: 10.1002/ar.21523. Epub 2011 Dec 21.
Metastasis and multidrug resistance (MDR) are the main reasons for the poor prognosis of non-small cell lung cancer (NSCLC) patients. The use of biomarkers may contribute to a more accurate prediction of tumor metastasis, a better response to chemotherapy, and better patient survival. Gelsolin-like actin-capping protein (CapG) and gelsolin have been identified as playing important roles in tumor invasion and metastasis. Permeability glycoprotein (P-gp), glutathione S-transferase pi (GSTP1), and topoisomerase-II (Topo-II) are proteins that are closely related to MDR. In this study, we assessed the prognostic significance of CapG and gelsolin (both markers of tumor motility), and of P-gp, GSTP1, and Topo-II (markers of MDR) in NSCLC patients. One hundred and twenty-one patients with pathologically confirmed, resectable NSCLC were included in the study. The expression levels of the five kinds of proteins mentioned above were determined by immunohistochemistry (IHC). The correlation between the clinical characteristics and IHC findings were analyzed. Expression of CapG, gelsolin, and P-gp was found to be associated with an increased risk of death (Hazard Ratio (HR) = 2.799, 95% Confidence Interval (CI) = 1.2705-6.169, P = 0.011; HR = 3.968, 95% CI = 1.811-8.693, P = 0.001; HR = 3.251, 95% CI = 1.456-7.260, P = 0.004, respectively), whereas expression of GSTP1 and Topo-II was not. These results suggest that higher tumor motility and MDR may be important in NSCLC prognosis.
转移和多药耐药 (MDR) 是非小细胞肺癌 (NSCLC) 患者预后不良的主要原因。生物标志物的应用可能有助于更准确地预测肿瘤转移、更好地对化疗做出反应以及改善患者的生存。胶凝蛋白样肌动蛋白加帽蛋白 (CapG) 和胶凝蛋白已被确定在肿瘤侵袭和转移中发挥重要作用。多药耐药相关蛋白包括： 多药耐药相关蛋白 1（P-gp）、谷胱甘肽 S-转移酶 pi（GSTP1）和拓扑异构酶 II（Topo-II）。在本研究中，我们评估了 CapG 和胶凝蛋白（肿瘤运动的标志物）以及 P-gp、GSTP1 和 Topo-II（MDR 标志物）在 NSCLC 患者中的预后意义。本研究纳入了 121 例经病理证实的可切除 NSCLC 患者。通过免疫组织化学 (IHC) 测定了上述 5 种蛋白质的表达水平。分析了临床特征与 IHC 结果之间的相关性。CapG、胶凝蛋白和 P-gp 的表达与死亡风险增加相关（风险比 (HR) = 2.799，95%置信区间 (CI) = 1.2705-6.169，P = 0.011；HR = 3.968，95% CI = 1.811-8.693，P = 0.001；HR = 3.251，95% CI = 1.456-7.260，P = 0.004），而 GSTP1 和 Topo-II 的表达则不然。这些结果表明，肿瘤运动性和 MDR 较高可能是 NSCLC 预后的重要因素。
